Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 1.58 is 70800% above its 3-year average of 0.00, near the high end of its 3-year range (-0.10–1.58).
As of the fiscal period ended Tuesday, June 30, 2026. 166.11% above its 12-month average of 0.59.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 1.58.
DEBT TO EQUITY RATIO
1.58
DEBT TO EQUITY RATIO AVG TTM
0.59
DEBT TO EQUITY RATIO AVG 3Y
0.00
DEBT TO EQUITY RATIO AVG 5Y
N/A
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+166.11%
CURRENT VS 3Y AVG
+55044.07%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11
median of 774 covered companies
CURRENT VS SECTOR MEDIAN
+1333.36%
vs the sector median at left
Zenas BioPharma, Inc.
Market Cap
$1.70B
Debt to Equity Ratio
1.58
TTM Avg
0.59
3Y Avg
0.00
5Y Avg
N/A
Market Cap
$1.71B
Debt to Equity Ratio
1.71
TTM Avg
1.50
3Y Avg
1.07
5Y Avg
0.87
Market Cap
$1.73B
Debt to Equity Ratio
0.10
TTM Avg
0.19
3Y Avg
0.15
5Y Avg
0.12
Market Cap
$1.74B
Debt to Equity Ratio
1.25
TTM Avg
2.57
3Y Avg
1.73
5Y Avg
2.08
Market Cap
$1.74B
Debt to Equity Ratio
N/A
TTM Avg
2.76
3Y Avg
3.57
5Y Avg
2.66
Market Cap
$1.75B
Debt to Equity Ratio
2.40
TTM Avg
2.21
3Y Avg
1.86
5Y Avg
2.71
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Zenas BioPharma, Inc. (ZBIO) | $1.70B | 1.58 | 0.59 | 0.00 | N/A |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.71B | 1.71 | 1.50 | 1.07 | 0.87 |
| Personalis, Inc. (PSNL)vs › | $1.71B | 0.16 | 0.18 | 0.24 | 0.20 |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.73B | 0.10 | 0.19 | 0.15 | 0.12 |
| Alignment Healthcare, Inc. (ALHC)vs › | $1.74B | 1.25 | 2.57 | 1.73 | 2.08 |
| Xeris Biopharma Holdings, Inc. (XERS)vs › | $1.74B | N/A | 2.76 | 3.57 | 2.66 |
| Absci Corporation (ABSI)vs › | $1.74B | 0.01 | 0.04 | 0.07 | 0.09 |
| Novocure Ltd (NVCR)vs › | $1.74B | 0.69 | 1.38 | 1.43 | 1.35 |
| Surgery Partners, Inc. (SGRY)vs › | $1.75B | 2.40 | 2.21 | 1.86 | 2.71 |
| Generate Biomedicines, Inc. (GENB)vs › | $1.77B | 0.14 | N/A | N/A | N/A |
Debt/Equity
1.58
Current Ratio
9.93
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 1.58 |
| 2026-03-31 | 1.05 |
| 2025-12-31 | 0.33 |
| 2025-09-30 | 0.00 |
| 2025-06-30 | 0.00 |
| 2025-03-31 | 0.00 |
| 2024-12-31 | 0.00 |
| 2024-09-30 | 0.00 |
| 2024-06-30 | 0.00 |
| 2024-03-31 | -0.09 |
| 2023-12-31 | -0.09 |
| 2023-09-30 | -0.10 |
| 2023-06-30 | 0.00 |
| 2023-03-31 | 0.00 |
| 2022-12-31 | 0.00 |
